{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000073","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.072752+00:00","generated_at":"2026-05-30T01:58:52.025875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues","bullets":["Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.","Cash $41.6M at Sep 30, 2024, up from $9.4M at Dec 31, 2023, boosted by private placement and ATM.","R&D spend $3.2M (up from $2.8M) on higher indirect costs; G&A $3.3M (up from $2.5M) due to share-based and legal.","Cadisegliatin program under FDA clinical hold since July 2024; company addressing basis for hold.","No revenue in Q3 2024; YTD revenue $1.0M from prior periods."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000073","json":"https://secwatch.observer/filing/0001641489-24-000073.json","markdown":"https://secwatch.observer/filing/0001641489-24-000073.md","text":"https://secwatch.observer/filing/0001641489-24-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/0001641489-24-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/vtvt-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:58:52.025875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}